Logo - springer
Slogan - springer

Biomedical Sciences - Neuroscience | Journal of NeuroImmune Pharmacology (Editorial Board)

Journal of Neuroimmune Pharmacology

Journal of Neuroimmune Pharmacology

Editor-in-Chief: Howard Gendelman

ISSN: 1557-1890 (print version)
ISSN: 1557-1904 (electronic version)

Journal no. 11481

$99.00 Personal Rate e-only for the Americas
Get Subscription

Online subscription, valid from January through December of current calendar year

Immediate access to this year's issues via SpringerLink

1 Volume(-s) with 4 issue(-s) per annual subscription

Automatic annual renewal

More information: >> FAQs // >> Policy

Editor-in-Chief:

Howard E. Gendelman
Carol Swarts, MD Emerging Neuroscience Research Laboratory
Department of Pharmacology and Experimental Neuroscience
University of Nebraska Medical Center
Omaha, NE   USA
hegendel@unmc.edu


Senior Editors:

Kalipada Pahan
Department of Neurological Sciences
Rush University Medical Center
Chicago, IL USA
Kalipada_Pahan@rush.edu

Raymond Chuen-Chung Chang
Department of Anatomy
Faculty of Medicine
The University of Hong Kong,
Hong Kong SAR, China
rccchang@hku.hk

Section Editors:

Neuroactive and Abused Substances
Guy Cabral
Virginia Commonwealth University
Department of Microbiology and Immunology
1101 East Marshall Street
Richmond, Virginia, USA
gacabral@vcu.edu

Imaging and Biomarkers
Linda Chang
Department of Medicine
University of Hawaii
Honolulu, Hawaii, USA
ichang@hawaii.edu

Neurotransmitters
Marco Cosentino
Center for Research in Medical Pharmacology
University of Insubria
Varese, Italy
marco.cosentino@uninsubria.it

Visual Neuromedicine
Harris Gelbard
Center for Neural Development and Disease
University of Rochester Medical Center
Rochester, NY, USA
harris_gelbard@urmc.rochester.edu

Neurodegenerative Disorders
Tsuneya Ikezu
Department of Pharmacology and Experimental Therapeutics
Boston University School of Medicine
Boston, Massachusetts, USA
tikezu@bu.edu

Infectious Diseases and Immunomodulation
Steve Jacobson
Viral Immunology Section
Neuroimmunology Branch, NINDS
Bethesda, Maryland, USA
jacobsons@ninds.nih.gov

Drug Delivery and Nanomedicine
Ram I. Mahato
Department of Pharmaceutical Sciences
College of Pharmacy
University of Nebraska Medical Center
Omaha, Nebraska, USA
ram.mahato@unmc.edu

Cell Signaling and Immunity
Thomas J. Rogers
Fels Institute For Cancer Research And Molecular Biology
Department of Pharmacology
Temple University School of Medicine
Philadelphia, Pennsylvania, USA
rogerst@temple.edu

Managing Editor:

Robin Taylor
Project Coordinator
Department of Pharmacology and Experimental Neuroscience
University of Nebraska Medical Center
Omaha, Nebraska, USA
email: jnip@unmc.edu
telephone: 402-559-3565

Editorial Board:

Martin Adler
Center for Substance Abuse Resources
Temple University School of Medicine
Philadelphia, Pennsylvania, USA

Aftab Ansari
Department of Pathology
Emory University School of Medicine
Atlanta, Georgia, USA

Stanley Appel
Department of Neurology
Methodist Neurological Institute
Houston, Texas, USA

Larry Benowitz
Department of Neurosurgery
Children's Hospital
Boston, Massachusetts, USA

Etty Benveniste
Department of Cell Biology
University of Alabama at Birmingham
Birmingham, Alabama, USA

Jean Bidlack
Department of Pharmacology and Physiology
University of Rochester Medical School
Rochester, New York, USA

Kathleen Boesze-Battaglia
Department of Biochemistry
University of Pennsylvania
Philadelphia, Pennsylvania, USA

Shilpa Buch
Department of Pharmacology and Experimental Neuroscience
University of Nebraska Medical Center
Omaha, Nebraska, USA

Tricia Burdo
Department of Neuroscience
Temple University Medical Center
Philadelphia, Pennsylvania, USA

Iain L. Campbell
University of Sydney
School of Molecular and Microbial Biosciences
Sydney, Australia

Sulie L. Chang
Department of Biological Sciences
Seton Hall University
South Orange, New Jersey, USA

Vladimir P. Chekhonin
Department of Biological Psychiatry
Moscow, Russia

Sheng-Di Chen
Department of Neurology
Rui Jin Hospital
Shanghai Jiaotong University School of Medicine
Shanghai, China

Zhiwei Chen
AIDS Institute
Department of Microbiology
The University of Hong Kong
Hong Kong

Carol Colton
Department of Neurology
Duke University
Durham, NC, USA

Ileana Cristea
Department of Molecular Biology
Princeton University
Princeton, New Jersey, USA

Tiziano Croci
Research Center Sanofi Midy
Milan, Italy

Toby Eisenstein
Temple University Medical Center
Philadelphia, Pennsylvania, USA

Nazira El-Hage, Ph.D.
Associate Professor
Florida International University
Department of Immunology
Herbert Wertheim, College of Medicine
Miami, FL 33199

Ronald Ellis
Department of Neurosciences
University of California, San Diego
San Diego, California

Howard Fox
Department of Pharmacology and Experimental Neuroscience
University of Nebraska Medical Center
Omaha, Nebraska, USA

Robert Fujinami
University of Utah
Salt Lake City, Utah, USA

Doina Ganea
Temple University
Philadelphia, Pennsylvania, USA

Gwenn Garden
University of Washington
Seattle, Washington, USA

Philippe Gasque
University of La Reunion
CYROI
St. Denis, Reunion Island

Thiago C. Genaro-Mattos
Department of Chemistry
Vanderbilt University
Nashville, Tennessee

Kurt Hauser
Department Pharmacology and Toxicology
Virginia Commonwealth University
Richmond, Virginia, USA

Johnny He
Department of Microbiology and Immunology
Indiana University
Indianapolis, Indiana, USA

William F. Hickey
Department of Pathology
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, USA

Etienne Hirsch
Research Center of Brain and Spinal Cord
INSERM, CNRS and Pierre and Marie Curie University
Paris, France

WenZhe Ho
Department of Pathology and Laboratory Medicine
Temple University
Philadelphia, Pennsylvania, USA

Pooja Jain
Department of Microbiology and Immunology
Drexel University College of Medicine
Doylestown, Pennsylvania, USA

Kelly L. Jordan-Sciutto
Department of Pathology 
University of Pennsylvania Dental School
Philadelphia, Pennsylvania, USA

Anumantha Kanthasamy
College of Veterinary Medicine
Iowa State University
Ames, Iowa, USA

Marcus Kaul
Sanford Burnham Prebys Medical Discovery Institute
University of California, San Diego
San Diego, California

Peter G.E. Kennedy
Division of Clinical Neuroscience
Institute of Neurological Sciences University of Glasgow
Glasgow, UK

Dennis Kolson
Department of Neurology
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania, USA

Anil Kumar
Division of Pharmacology
University of Missouri-Kansas City
Kansas City, Missouri, USA

Santosh Kumar
College of Pharmacy
University of Tennessee Health Science Center
Memphis, Tennessee, USA

Hans Lassmann
Medical University of Vienna
Center for Brain Research
Wien, Austria

Sunhee C. Lee
Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
Department of Pathology
Bronx, NY, USA 

Stuart Lipton        
Department of Neurology
Burnham Institute Center for Neuroscience
LaJolla, CA, USA

Eugene Major
Laboratory of Molecular Medicine and Neuroscience
National Institute of Neurological Disease and Stroke
Bethesda, Maryland, USA

Eliezer Masliah
Departments of Neurosciences and Pathology
University of California, San Diego
LaJolla, CA, USA

Raphael Mechoulam
Department of Medicinal Chemistry and Natural Products
Hebrew University of Jerusalem
Jerusalem, Israel

Olimpia Meucci
Department of Pharmacology & Physiology
Drexel University College of Medicine
Philadelphia, Pennsylvania, USA

Richard Miller
Department of Molecular Pharmacology
Northwestern University
Chicago, IL, USA

David Morgan
Department of Pharmacology
University of South Florida
Tampa, Florida, USA

James O'Callaghan
Center for Disease Control and Prevention, NIOSH
Morgantown, West Virginia, USA

V. Hugh Perry
Biological Sciences
University of Southampton
Southampton, England, UK

Yuri Persidsky
Department of Pathology and Laboratory Medicine
Temple University
Philadelphia, PA

Phillip Peterson
Department of Medicine
Hennepin County Medical Center
Minneapolis, Minnesota, USA

Phillip Popovich
Department of Neuroscience
Ohio State University
Columbus, OH 43210

Serge Przedborski
Center for Neurobiology and Behavior
Columbia University
New York, New York, USA

Jay Rappaport
Center for Neurovirology and Cancer Biology
Temple University
Philadelphia, Pennsylvania, USA

Sabita Roy
Department of Pharmacology and Surgery
University of Minnesota
Minneapolis, Minnesota, USA

Virginia Sanders
College of Medicine and Public Health
Molecular Virology, Immunology and Medical Genetics
Ohio State University
Columbus, Ohio, USA

Michal Schwartz
Department of Neurobiology
The Weizmann Institute of Science
Rehovot, Israel

Burt Sharp
Department of Pharmacology
University of Tennessee Health Science Center
Memphis, Tennessee, USA

Bruce Shiramizu
University of Hawaii Medical Center
Manoa, Hawaii, USA

Prati Pal Singh
National Institute of Pharmaceutical Education and Research
Punjab, India

Gary Siuzdak
Center for Mass Spectrometry
The Scripps Research Institute
LaJolla, CA, USA

Christoph Stein
Department of Anesthesiology
Freie Universitaet Berlin
Berlin, Germany

Antonio Uccelli
Department of Experimental Medicine
University of Genoa and San Martino Hospital
Genoa, Italy

Linda Jo Van Eldik
Department of Anatomy and Neurobiology
University of Kentucky
Lexington, Kentucky, USA

Charles Wood
Nebraska Center for Virology
University of Nebraska Lincoln
Lincoln, Nebraska, USA

Bryan K. Yamamoto
Department of Pharmacology and Toxicology
Indiana University
Indianapolis, IN, USA

Yaoying Zeng
Institute for Tissue Transplantation and Immunology
Jinan University, Guangzhou, China

Meet the Editors of JNIP 

Meet the Editors of JNIP

The Journal of Neuroimmune Pharmacology is published under the leadership of a team of dedicated scientists. We invite you to meet the Editors by reading their biographical portraits below.

Howard E. Gendelman, Editor-in-Chief 

Gendelman
Dr. Howard Gendelman is the Margaret R. Larson Professor of Medicine and Chair of the Department of Pharmacology and Experimental Neuroscience and Director of the Center for Neurodegenerative Disorders at the University of Nebraska Medical Center.
He received his medical degree from Pennsylvania State University followed by fellowship training and faculty appointments at the Albert Einstein College of Medicine, the Johns Hopkins University Medical Center, the National Institutes of Health, and the Walter Reed Army Institute of Research. He has gained international attention for his work on common mechanisms of nerve damage in Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis, and HIV-1-associated dementia.
His research has lead to groundbreaking discoveries on how inflammation causes nerve cell damage and how drugs and vaccines can be used to reverse it.

Kalipada Pahan, Senior Editor 

Pahan, Author
Kalipada Pahan is a Professor of Neurological Sciences and the Floyd A. Davis Endowed Chair of Neurology in the Department of Neurological Sciences at the Rush University Medical Center in Chicago. Born in West Bengal, India, in 1964, he received his Ph.D. degree in Biochemistry in 1992 from the University of Calcutta, India, and pursued a postdoctoral training in Biochemistry and Neuroimmunology at the Medical University of South Carolina.
Dr. Pahan is engaged in translational research involving glial and neuronal cell signaling, proinflammatory transcription factors, nitric oxide, and ceramide with an emphasis on drug discovery for neuroinflammatory and neurodegenerative disorders such as multiple sclerosis, Parkinson's disease, Alzheimer's disease, HIV-associated dementia. He has over 100 publications including research articles, reviews and book chapters.

Guy Cabral, Section Editor: Neuroactive and Abused Substances 

Cabral, Author
Guy A. Cabral is a Professor in the Department of Microbiology and Immunology in the School of Medicine at Virginia Commonwealth University. He received the B. S. degree in Zoology from the University of Massachusetts (Amherst, MA) and the M.S. and Ph.D. degrees from the University of Connecticut (Storrs, Ct) and pursued postdoctoral training in virology at Baylor College of Medicine (Houston, TX).
Dr. Cabral’s research centers on assessment of immunomodulatory effects of drugs of abuse and other pharmacological agents on the immune system. Of particular interest has been definition of the role of cannabinoids in altering the activities of macrophages and macrophage-like cells, including microglia in the central nervous system. This focus has extended to investigating the functional relevance of cannabinoid receptors in host resistance to viral and opportunistic protozoon infections.

Linda Chang, Section Editor: Imaging and Biomarkers  

Chang, Author
Linda Chang is a Professor of Medicine at the University of Hawaii's John A. Burns School of Medicine, and Co-Director of the Neuroscience and Imaging Research Program at Queens Medical Center in Honolulu.
After completing her medical training at Georgetown University, Neurology Residency and Fellowships at UCLA, she was appointed as a Faculty member in 1992 in the Department of Neurology at UCLA School of Medicine. In 2000, she was recruited to serve as Chair of the Medical Department at Brookhaven National Laboratory, and in 2004, she relocated to Hawaii in order to continue her research in the effects of methamphetamine on the brain. She also received several honors and awards, including the Richard E. Weitzman Award in Biochemical Research in 1998 and the Brookhaven Woman of Science Award in 2001.
In addition, she received three career development awards from NIH, including the Clinical Associate Physician Award through the NCRR/GCRC program, and two Clinician Scientist Career Development Awards from NIDA. She is dedicated to both research and to mentor junior clinician scientists.
Her scientific interest and that of her laboratory included the application of advanced neuroimaging techniques [including MRI, positron emission tomography (PET) and SPECT] to investigate the neuropathophysiology of HIV, substance abuse, normal aging and development, as well as other neuropsychiatric disorders. Her research is supported by the NIH (NIDA, NIMH, NINDS, NCRR), the ONDCP and the University of Hawaii.

Raymond Chang, Section Editor: Natural Medicine 

Raymond Chang
Dr. Raymond Chang received his BSc and MPhil in Biochemistry, Neurochemistry and Neuroanatomy in Hong Kong, China. His doctoral works were performed as a German Academic Exchange Student investigating neurophysiology and clinical neuroscience at the University of Munich, Munich, Germany. Postdoctoral training was performed in neuroimmunology, neuropharmacology, and molecular neuroscience at the National Institutes of Health, USA.
He has published over 90 peer-reviewed papers and book chapters in the field of neurosciences. His research interests currently center around works seeking to elucidate the molecular mechanisms of Alzheimer’s and Parkinson’s diseases (AD and PD) and their related neuroimmune responses. He heads the Laboratory of Neurodegenerative Diseases in Hong Kong that investigates the role played by beta-amyloid aggregation and autophagy in the pathobiology of AD. Mitochondria function and cellular clearing mechanisms including the ubiquitin proteasome system are actively studied with the goal in achieving the elimination of tau and other aggregated proteins that can induce disease.
These and other disease events are being investigated with an eye towards developing herbal medicines that would be used to slow or attenuate the severity or course of AD and PD. Studies of how such medicines can affect a broad range of aging co-morbidites in AD and PD are pursued that include depression, abused substances, obesity, hypertension and systemic inflammation. All can modulate neuroimmune responses that are linked to progressive age-related diseases.

Marco Cosentino, Section Editor: Neurotransmitters 

P_Cosentino-JNIP_95x120px
Dr. Marco Cosentino is Professor of Pharmacology and Chair of the Center for Research in Medical Pharmacology at the University of Insubria, Varese (I).
Dr. Cosentino received the medical degree cum laude from the University of Pavia and the PhD degree in Pharmacology and Toxicology from the University of Turin. He was appointed as member of the II Faculty of Medicine of the University of Pavia and thereafter as member of the Faculty of Medicine at the University of Insubria. Dr. Cosentino very soon concentrated his research interests on neuro- and immunopharmacology and specifically on dopaminergic and adrenergic pathways in the neuroimmune network, which has been his main area of investigation during the last two decades. During all this period, together with his research group, he developed several original strategies and techniques for the study of dopaminergic and adrenergic mechanisms in immune cells, including measurement of receptor expression and function, ex vivo/in vitro functional assays for the phenotipization and functional characterization of innate and adaptive immunity in health and disease, including pharmacogenetic approaches. His overarching goal is to provide a sound scientific background for the repurposing of established adrenergic and dopaminergic therapeutics as novel immunomodulating agents in neuroimmune diseases.
His research has provided major contribution to unravel the importance of endogenous production of the catecholamines dopamine, noradrenaline and adrenaline in human immune cells, as well as the involvement of dopaminergic and adrenergic neuroimmune mechanisms in major diseases such as multiple sclerosis, rheumatoid arthritis, cancer, and Parkinson's disease.

Harris A. Gelbard, Section Editor: Visual Neuromedicine 

Harris Gelbard
Harris Gelbard is Professor of Neurology, Microbiology and Immunology, and Pediatrics and Director of the Center for Neural Development and Disease, University of Rochester Medical Center. Dr. Gelbard received his MD/PhD-Pharmacology in 1983 from Northwestern University Medical School, Chicago, Ill and joined the University of Rochester Medical Center in 1989.
Dr. Gelbard's research focuses on how HIV-1 and its constituent proteins disrupt the normal function(s) of two enzyme targets, glycogen synthase kinase 3 beta (GSK-3β) and mixed lineage kinase 3 (MLK3) in neurons, macrophages and microglia, with the ultimate goal of designing small molecule therapies to prevent their pathologic activation seen in neuroinflammatory and neurodegenerative disorders.
His research has made particularly important strides in developing striking visual presentations of research discovery. For example, he has adapted visual chronic thin-skull window methods for use in closely monitoring the biology, physiology, and molecular profiles of murine microglia in vivo over time using two-photon microscopy. His laboratory is at the cutting edge of visual experiments towards linking accessible translucent thinned-skull cortical windows for continuous observations of cellular events in the brain seen during disease and neurorepair.
He has over 20 years of continuous research support from the National Institutes of Health (NIMH, NINDS) and is well published in the fields of neuropharmacology, neurovirology, and neuroimmunity.

Steven Jacobson, Section Editor: Infectious Diseases and Immunomodulation 

Jacobson, Author
Dr. Jacobson received his B.A. from Temple University and his Ph.D. from the Rennselear Polytechnic Institute where he earned his degree in Virology. The focus of his research was on persistent virus infections.
In 1981, Dr. Jacobson joined the Neuroimmunology Branch as a postdoctoral research fellow in immunology as a National Multiple Sclerosis Society Fellow. In 1993, he received tenure and formed the Viral Immunology Section to study the role of human viruses in the pathogenesis of chronic progressive neurologic disease.
Dr. Jacobson's laboratory is studying virological, immunological, and molecular mechanisms associated with the human T lymphotropic virus type-I associated myelopathy/tropical spastic paraparesis and the association of virus in multiple sclerosis.

Ram I. Mahato, Section Editor: Drug Delivery and Nanomedicines 

Portrait_Mahato_128px
Ram I. Mahato is a Professor and Chairman of the Department of Pharmaceutical Sciences at the University of Nebraska Medical Center. He was a Professor of Pharmaceutical Sciences at the University of Tennessee Health Science Center, Research Assistant Professor at the University of Utah, Senior Scientist at GeneMedicine, Inc., and postdoc at the University of Southern California in Los Angeles, Washington University in St. Louis, and Kyoto University. He received PhD in Drug Delivery from the University of Strathclyde, UK and BS from China Pharmaceutical University, Nanjing. He has published 116 papers, holds 2 US patents, and has edited/written eight books and eleven journal issues. He was a Feature Editor of Pharmaceutical Research (2006-2013). He is a CRS Fellow, AAPS Fellow, Permanent Member of BTSS/NIH Study section (2009-2013). His research has provided unique insight into the design of nucleic acid delivery and gene expression systems, factors influencing their biodistribution and gene expression or silencing for improved islet transplantation and treatment of liver fibrosis and cancer.

Tsuneya Ikezu, Section Editor: Neurodegenerative Disorders 

Portrait_Ikezu_Author_95px
Dr. Tsuneya Ikezu completed his undergraduate, medical and graduate educations at University of Tokyo (M.D. in 1991 and Ph.D. 1997). After completing post-doctoral trainings at Massachusetts General Hospital (Molecular Pharmacology) and Cleveland Clinic Foundation (Neuroscience), he joined the faculty as Assistant Professor of Pathology and Deputy Director of the Center for Neurovirology and Neurodegenerative Disorders at University of Nebraska Medical Center, where he worked for 10 years. In 2010, he moved to Boston University School of Medicine as Professor in the Department of Pharmacology and Experimental Therapeutics with joint appointments in the Department of Neurology and Boston University Alzheimer’s Disease Center. He also leads the Laboratory of Molecular NeuroTherapeutics. Dr. Ikezu’s research interests are focused on the role of microglia and neuroinflammation as a part of pathophysiology and pharmacologic intervention of Alzheimer’s and Parkinson’s diseases, and autism spectrum disorders.

Thomas J. Rogers, Section Editor: Cell Signaling and Immunity  

Grey, Roger, Author
Thomas J. Rogers was born in Dayton, Ohio, home of Wilbur and Orville Wright, and earned his Ph.D. degree from the University of Wisconsin, Madison in 1976. After working as a post-doctoral fellow at the Roche Institute of Molecular Biology, he joined the faculty of the Microbiology Department at Oregon State University in 1978.
In 1981 he moved to Temple University School of Medicine as a faculty member in the Microbiology and Immunology Department. He is currently a member of the Department of Pharmacology, the Fels Institute for Cancer Research and Molecular Biology, and a Senior Investigator in the Center for Substance Abuse Research.
His research interests are in the regulation of G protein-coupled receptor expression and function, and the cross-talk between these receptors in the regulation of inflammatory processes. His most recent research efforts have focused on the interactions of opioid and chemokine receptors, and the regulation of expression of these receptors and their ligands. He is also interested in the role of cytokines and chemokines in the generation of inflammatory diseases, and inflammatory processes associated with microbial infections.
He has been the recipient of continuous funding from the National Institutes of Health since 1981. He has trained 20 doctoral students, 17 post-doctoral fellows during his academic career, and has a commitment to the training of young scientists.

Robin Taylor, Managing Editor 

Taylor
Robin Taylor is the Project Coordinator of the Department of Pharmacology and Experimental Neuroscience at the University of Nebraska Medical Center and Managing Editor of the Journal of Neuroimmune Pharmacology. Her computer, literary, and graphic skills play a seminal role in building the department. As Managing Editors for JNIP, Ms. Taylor's work supports the directives of the Editor-in-Chief, Section and Guest Editors to best facilitate the journal's development together with its outreach activities. She remains a mainstay of journal activities and its growth.

For authors and editors


  • Journal Citation Reports®
    2017 Impact Factor
  • 3.664
  • Aims and Scope

    Aims and Scope

    Close

    The aims of the Journal of Neuroimmune Pharmacology are to promote the dissemination, interest, and exchange of new and important discoveries for the pharmacology and immunology of the nervous system. The aims parallel that of the Society on NeuroImmune Pharmacology by increasing the fundamental understanding of neurologic and neuropsychiatric disorders affected by the immune system or vice versa and towards pharmacologic measures that lead, either to a better understanding of disease mechanisms, or by improving disease outcomes. The scope of JNIP includes all primary works and reviews into the etiology, prevention, and treatment of neuroimmune and nervous system diseases affected by disordered immunity. Original studies serving to define neuroimmune modulation of environmental or endogenous cues such as toxins and drugs of abuse, hormones, and cytokines are welcome. JNIP will serve as a reliable source of interdisciplinary information bridging the fields of pharmacology, immunology, and neuroscience.

  • Submit Online
  • Open Choice - Your Way to Open Access
  • Instructions for Authors

    Instructions for Authors

    Close

  • Message from the Editor-in-Chief

    Message from the Editor-in-Chief

    Close

  • Author Academy: Training for Authors
  • Copyright Information

    Copyright Information

    Close

    Copyright Information

    For Authors

    Submission of a manuscript implies: that the work described has not been published before (except in form of an abstract or as part of a published lecture, review or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors, if any, as well as – tacitly or explicitly – by the responsible authorities at the institution where the work was carried out.

    Author warrants (i) that he/she is the sole owner or has been authorized by any additional copyright owner to assign the right, (ii) that the article does not infringe any third party rights and no license from or payments to a third party is required to publish the article and (iii) that the article has not been previously published or licensed. The author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors. Transfer of copyright to Springer (respective to owner if other than Springer) becomes effective if and when a Copyright Transfer Statement is signed or transferred electronically by the corresponding author. After submission of the Copyright Transfer Statement signed by the corresponding author, changes of authorship or in the order of the authors listed will not be accepted by Springer.

    The copyright to this article, including any graphic elements therein (e.g. illustrations, charts, moving images), is assigned for good and valuable consideration to Springer effective if and when the article is accepted for publication and to the extent assignable if assignability is restricted for by applicable law or regulations (e.g. for U.S. government or crown employees).

    The copyright assignment includes without limitation the exclusive, assignable and sublicensable right, unlimited in time and territory, to reproduce, publish, distribute, transmit, make available and store the article, including abstracts thereof, in all forms of media of expression now known or developed in the future, including pre- and reprints, translations, photographic reproductions and microform. Springer may use the article in whole or in part in electronic form, such as use in databases or data networks for display, print or download to stationary or portable devices. This includes interactive and multimedia use and the right to alter the article to the extent necessary for such use.

    Authors may self-archive the Author's accepted manuscript of their articles on their own websites. Authors may also deposit this version of the article in any repository, provided it is only made publicly available 12 months after official publication or later. He/she may not use the publisher's version (the final article), which is posted on SpringerLink and other Springer websites, for the purpose of self-archiving or deposit. Furthermore, the Author may only post his/her version provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".

    Prior versions of the article published on non-commercial pre-print servers like arXiv.org can remain on these servers and/or can be updated with Author's accepted version. The final published version (in pdf or html/xml format) cannot be used for this purpose. Acknowledgement needs to be given to the final publication and a link must be inserted to the published article on Springer's website, accompanied by the text "The final publication is available at link.springer.com". Author retains the right to use his/her article for his/her further scientific career by including the final published journal article in other publications such as dissertations and postdoctoral qualifications provided acknowledgement is given to the original source of publication.

    Author is requested to use the appropriate DOI for the article. Articles disseminated via link.springer.com are indexed, abstracted and referenced by many abstracting and information services, bibliographic networks, subscription agencies, library networks, and consortia.

    For Readers

    While the advice and information in this journal is believed to be true and accurate at the date of its publication, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may have been made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

    All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher (respective the copyright owner if other than Springer). The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

    Springer has partnered with Copyright Clearance Center's RightsLink service to offer a variety of options for reusing Springer content. For permission to reuse our content please locate the material that you wish to use on link.springer.com or on springerimages.com and click on the permissions link or go to copyright.com, then enter the title of the publication that you wish to use. For assistance in placing a permission request, Copyright Clearance Center can be connected directly via phone: +1-855-239-3415, fax: +1-978-646-8600, or e-mail: info@copyright.com.


    © Springer Science+Business Media New York

Alerts for this journal

 

Get the table of contents of every new issue published in Journal of Neuroimmune Pharmacology.